News
Amivantamab + Lazertinib Shows Significant Benefits in EGFR-Mutant NSCLC
Johnson & Johnson’s Innovative Medicine (formerly Janssen) reported that the combination of amivantamab (Rybrevant®) and lazertinib (Leclaza® in Korea, Lazcluze® internationally), developed by Yuhan Corporation,
Hiring – Business Development Manager
Business Development Manager Yuhan USA Corporation Work locations: Cambridge, MA Employee type: Full-time Contact Information: info@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a
Janssen Gains China Approval for Lazertinib + Amivantamab Combo in EGFR-Mutant NSCLC
Date: 08/01/25 Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global
Hiring – Part-time Operations Associate/Executive Assistant
Part-time Operations Associate/Executive AssistantYuhan USA CorporationWork locations: Cambridge, MAEmployee type: part-timeContact Information: yjlee@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a wholly owned
Yuhan Presents Phase 1b Part 2 Results for Lesigercept – Shows Efficacy in Omalizumab-Refractory Patients
Date: 6/13/25 Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in
Yuhan Corporation Receives $15 Million Milestone from Janssen for Launch of Lazertinib + Amivantamab Combination Therapy in Japan
Yuhan Corporation announced that it will receive a milestone payment of $15 million (approximately 20.7 billion KRW) from Janssen Biotech, a subsidiary of the multinational